Insight

Jun 10, 2024, 00:53

Vijith Shetty: Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC

Vijith Shetty, Associate Professor and Consultant Medical Oncologist at KS Hegde Medical Academy, shared on LinkedIn:

“Osimertinib Could Alter SOC for Stage III EGFR+ Non Small Cell Lung Cancer (NSCLC).

Osimertinib reduced the risk of progression or death by 84% compared to placebo in EGFR-mutated, unresectable stage III NSCLC.

Median PFS was 39.1 months for osimertinib versus 5.6 months for placebo.

The 12- and 24-month PFS rates for osimertinib were 74% and 65%, respectively, compared to 22% and 13% for placebo.

Osimertinib’s safety profile was consistent with known data, with most adverse effects being manageable and not leading to treatment discontinuation.

These results position osimertinib as the new standard of care post-chemoradiotherapy for patients with EGFR-mutated, locally advanced NSCLC.”

Additional information.
Source: Vijith Shetty/LinkedIn

cancer Chih-Liang Wang Dana C. Ghiorghiu Dang-Van Khiem Eduardo Cronemberger EGFR-mutation Ignacio Casarini James Chih-Hsin Yang KS Hegde Medical Academy Le-Van Quang Manuel Cobo Meijuan Huang Mustafa Özgüroğlu Myung-Ju Ahn non small cell lung cancer Nopadol Soparattanapaisarn NSCLC OncoDaily Oncology osimertinib Osimertinib safety Shun Lu Suresh S. Ramalingam Takako Inoue Terufumi Kato Toon van der Gronde Vijith Shetty Virote Sriuranpong Xiangning Huang Xiaorong Dong

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage